CIK 0001826457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-28 | Bolzon Bradley J PhD Director | Conversion · Series A convertible preferred stock | −20,004,280 | 0 | ||
| 2021-06-28 | Bolzon Bradley J PhD Director | Conversion · Series B convertible preferred stock | −3,000,000 | 0 | ||
| 2021-06-28 | Bolzon Bradley J PhD Director | Conversion · Series B convertible preferred stock | −4,150,000 | 0 | ||
| 2021-06-28 | Bolzon Bradley J PhD Director | Conversion · Series C convertible preferred stock | −2,699,328 | 0 | ||
| 2021-06-28 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +6,515,869 | 6,799,115 | ||
| 2021-06-28 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +1,940,043 | 1,940,043 | ||
| 2021-06-28 | Versant Venture Capital VI, L.P. 10% owner | Purchase | +157,895 | $19.00 | $3.0M | 2,097,938 |
| 2021-06-28 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series A convertible preferred stock | −20,004,280 | 0 | ||
| 2021-06-28 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series B convertible preferred stock | −3,000,000 | 0 | ||
| 2021-06-28 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series B convertible preferred stock | −4,150,000 | 0 | ||
| 2021-06-28 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series C convertible preferred stock | −2,699,328 | 0 | ||
| 2021-06-23 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +47,132 | 47,132 | ||
| 2021-06-23 | Wallace Owen B. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +113,298 | 113,298 | ||
| 2021-06-23 | Tamboli Ajim Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +56,649 | 56,649 | ||
| 2021-06-23 | Leo Chandra P. Director | Grant or award · Stock Option (Right to Buy) | +47,132 | 47,132 | ||
| 2021-06-23 | SCHIFF ANDREW N Director | Grant or award · Stock Option (Right to Buy) | +47,132 | 47,132 | ||
| 2021-06-23 | Blackwell Kimberly Director | Grant or award · Stock Option (Right to Buy) | +47,132 | 47,132 | ||
| 2021-06-23 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +387,069 | 387,069 | ||
| 2021-06-23 | Bolzon Bradley J PhD Director | Grant or award · Stock Option (Right to Buy) | +47,132 | 47,132 | ||
| 2021-06-23 | Siu Christine Director | Grant or award · Stock Option (Right to Buy) | +47,132 | 47,132 |
Page 15 of 16 · 310 trades